Rewriting the Calcium Code in ADH1

Faculty: Michael A. Levine, MD, ML, MACE Faculty: Aliya Khan, MD, FRCPC, FACP, FACE, FASBMR In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and highlight key efficacy and safety findings, including reductions in hypercalciuria and the potential implications for long-term renal health. The faculty also examine the role of genetic testing in establishing an accurate diagnosis, guiding family screening, and preparing clinicians for emerging precision medicine approaches in ADH1.